Stephen Yoder, Pieris CEO

As­traZeneca part­ner Pieris ends work on HER2 drug test­ed in com­bo with Eli Lil­ly, Seagen can­cer meds

As Pieris Phar­ma­ceu­ti­cals fa­vors an As­traZeneca-part­nered pro­gram in asth­ma, and be­cause the mid-stage study is tak­ing longer than ex­pect­ed, the biotech is de­cid­ing to end work on a HER2 drug.

The Boston biotech put out word Thurs­day that it’s end­ing the de­vel­op­ment of cin­re­ba­fusp al­fa (PRS-343), which was in a Phase II study for cer­tain HER2 gas­tric can­cers. Ear­li­er in its de­vel­op­ment, the 4-1BB/HER2 fu­sion pro­tein drug ran in­to a par­tial clin­i­cal hold in its Phase I in the sum­mer of 2020. De­spite that, Eli Lil­ly came to the ta­ble a month lat­er to con­tribute its ra­mu­cirum­ab (Cyra­mza) and pa­cli­tax­el for the Phase II study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.